Girish Gudi

GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis

Emma Guttman‐Yassky, Ana B. Pavel, Lisa Zhou et al. · Journal of Allergy and Clinical Immunology · 2019 · 222 citations · Full text

Medicine, Dermatology, Pharmacology +17

Randomized, double-blind, placebo-controlled trial of ISC 17536, an oral inhibitor of transient receptor potential ankyrin 1, in patients with painful diabetic peripheral neuropathy: impact of preserved small nerve fiber function

Ramanathan Balamurugan, Monika Tandon, Neelufar Mozaffarian et al. · Pain · 2021 · 55 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis

Barbara Rewerska, Lawrence Sher, Sady Alpizar et al. · Journal of Allergy and Clinical Immunology Global · 2023 · 44 citations · Full text

Life Sciences, Dermatology, Immunology +13

ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells

Laura Carretero-Iglesia, O. Hall, Jérémy Berret et al. · Nature Cancer · 2024 · 36 citations · Full text

Life Sciences, Immunology, Oncology +17

Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson’s disease model

Abhisek Banerjee, S. D. Patil, Mahesh Y. Pawar et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 34 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16